BALAXI NSE filing

Balaxi Pharma Q2 FY27 Revenue Up 45% to ₹8,137 Crore, PAT Surges 450%

The RealCase readHigh impact Positive

Balaxi Pharmaceuticals reported strong Q2 FY27 results with revenue up 45% to ₹8,137 lakh and PAT surging 450% to ₹115 lakh YoY. For H1 FY27, revenue increased 27.68% to ₹16,205 lakh, and PAT grew 390.30% to ₹244 lakh. The company added 31 new product registrations in H1 FY27.

Why it matters

The substantial increase in revenue and profit, along with positive management commentary on future growth strategies and operational improvements, is expected to have a significant impact on investor sentiment and the company's stock.

The market read

The company reported significant year-on-year growth in revenue, EBITDA, and PAT, indicating strong financial performance.

Balaxi Pharmaceuticals Limited announced its unaudited financial results for the second quarter (Q2 FY27) and half year (H1 FY27) ended September 30, 2026. The company reported a consolidated revenue from operations of ₹8,137.23 lakh for Q2 FY27, a 44.85% increase compared to ₹5,617.53 lakh in Q2 FY26. EBITDA surged by 338.19% to ₹512.07 lakh, with EBITDA margin improving to 6.29% from 2.08% year-on-year. Profit After Tax (PAT) saw a significant jump of 450.29% to ₹115.01 lakh, compared to ₹20.90 lakh in the same period last year. Diluted Earnings Per Share (EPS) increased to ₹0.21 from ₹0.04. For the half year ended September 30, 2026, revenue grew by 27.68% to ₹16,205.40 lakh, while PAT rose by 390.30% to ₹244.76 lakh.

Mr. Ashish Maheshwari, Chairman & Managing Director, commented that the pharmaceutical markets in Africa and Latin America continue to offer opportunities. Balaxi Pharmaceuticals is focused on strengthening its presence through its branded, IPR-driven business model, supported by an extensive product registration portfolio, local warehousing, and distribution network. In H1 FY27, 31 new product registrations were added. Latin America remains a key growth area, with a focus on Guatemala, Dominican Republic, Honduras, and El Salvador. The company is also working on improving operating efficiencies in Angola. With the Jadcherla manufacturing facility now operational, Balaxi aims to leverage in-house manufacturing, branded generics, and geographical expansion as key priorities to strengthen its competitive position.

Filing to action

What to do with a filing like this

BALAXI PHARMACEUTICALS LIMITED filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by BALAXI PHARMACEUTICALS LIMITED. Read the original for the full detail.

View original filing